Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Short term Debt (2019)

Summit Therapeutics (SMMT) has disclosed Short term Debt for 1 consecutive years, with $105000.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Short term Debt changed N/A year-over-year to $105000.0, compared with a TTM value of $105000.0 through Dec 2019, changed N/A, and an annual FY2019 reading of $105000.0, changed N/A over the prior year.
  • Short term Debt was $105000.0 for Q4 2019 at Summit Therapeutics.
  • Across five years, Short term Debt topped out at $105000.0 in Q4 2019 and bottomed at $105000.0 in Q4 2019.